|Bid||26.75 x 1200|
|Ask||27.48 x 800|
|Day's range||26.87 - 27.05|
|52-week range||15.92 - 28.17|
|Beta (5Y monthly)||1.52|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||28.25|
Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.
An increase in Intersect ENT's (XENT) operating costs puts pressure on its Q3 bottom line.
Intersect ENT (XENT) delivered earnings and revenue surprises of -14.29% and -17.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?